MALAKOFF, FRANCE – 19 April 2016 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy (US-guided High-Intensity Focused Ultrasound treatment), announces today that the University of Tübingen, Germany, has published an article in the “Senologie Journal” entitled “Thermosurgical ablation of breast fibroadenoma” (BFA), presenting its experience with the Echopulse system for the treatment of BFA. As the satisfactory study results have convinced Tübingen University to offer echotherapy in routine clinical practice to its patients, a commercial agreement has been concluded between Theraclion and the Institution.
Positive results of the clinical study on Echotherapy breast
Beginning in December 2013, the “Frauenklinik” of the University of Tübingen conducted a clinical study on 27 patients to evaluate the safety and efficacy of echotherapy for the treatment of breast fibroadenoma, which is the most common form of benign breast tumor.
Ad Statistics
Times Displayed: 22374
Times Visited: 452 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The University has published an article reporting its preliminary experience. The study demonstrates:
• FA volume was significantly reduced in all patients compared to baseline with complete ablation or downsizing of the FA.
• FA symptoms (including pain and discomfort) either disappeared or were significantly reduced following echotherapy.
• No recurrence or incidence of regrowth have been observed up to 12 months post treatment
• Echotherapy procedures were very well tolerated with a scar-free process providing good cosmetic outcomes while avoiding complications associated with surgical incisions.
• All patients reported high satisfaction levels and would recommend echotherapy to other persons or would repeat the procedure on a second FA.
The author of the article, Professor Markus Hahn, Chief Breast Surgeon at Tübingen University concluded: "Our results demonstrate that HIFU is a promising new treatment option for breast fibroadenoma".
Commercial agreement between Tübingen University and Theraclion to offer echotherapy in routine clinical practice
Based on positive results from its clinical study, the University of Tübingen has decided to sign a commercial agreement with Theraclion to offer echotherapy to its patients. Tübingen University is Germany’s first certified breast center and one of the most modern breast clinics in Europe. The Center is nationally and internationally recognized for its expertise in teaching and research. It performs more than 700 breast cancer surgeries every year.
